Trials / Conditions / Platinum-sensitive Ovarian Cancer

Platinum-sensitive Ovarian Cancer

12 registered clinical trials studyying Platinum-sensitive Ovarian Cancer — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maint NCT07225270	Genmab	Phase 3
Not Yet Recruiting	Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer NCT07454018	The First Affiliated Hospital of Soochow University	Phase 2
Not Yet Recruiting	RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) NCT07295132	Asan Medical Center	Phase 2
Recruiting	A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers NCT07024784	AbbVie	Phase 2
Recruiting	Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer NCT06686030	Akeso	Phase 2
Completed	Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors NCT05002868	Rhizen Pharmaceuticals SA	Phase 1
Unknown	Variance of HRD From Paired Ovarian Cancer NCT05069818	Xiaoxiang Chen	—
Active Not Recruiting	OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC NCT04713514	ARCAGY/ GINECO GROUP	Phase 2
Completed	Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer NCT04457089	Marc Goodman	EARLY_Phase 1
Terminated	Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovar NCT02978222	Marker Therapeutics, Inc.	Phase 2
Terminated	Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment NCT02035345	Massachusetts General Hospital	Phase 4
Completed	A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer NCT01847274	Tesaro, Inc.	Phase 3